文献速递消化系统肿瘤

曲氟尿苷/替匹嘧啶联合贝伐珠单抗对难治性转移性结直肠癌肿瘤缩小及缓解深度的影响:SUNLIGHT试验分析

Impact of trifluridine/tipiracil plus bevacizumab on tumor shrinkage and depth of response in refractory metastatic colorectal cancer: analysis of the SUNLIGHT trial.
PubMed 文献 · Eur J Cancer · 2025-07-12

SUNLIGHT试验的事后分析评估曲氟尿苷/替匹嘧啶(FTD/TPI)联合贝伐珠单抗与FTD/TPI单药在难治性转移性结直肠癌中的肿瘤缩小(TS)、早期肿瘤缩小(ETS)、肿瘤缩小持续时间(DTS)和缓解深度(DpR)。联合组48%出现TS、39%出现ETS,单药组分别为21%和17%。达到ETS的患者中,联合组中位DTS为3.8个月,单药组为2.1个月(HR 0.34,95%CI 0.22-0.53,P<0.0001)。联合组DpR幅度大于单药组。结论认为联合治疗生存获益可能与ETS和DpR改善相关。

要点

  • 联合组48%出现肿瘤缩小、39%出现早期肿瘤缩小,单药组分别为21%和17%。
  • 达到早期肿瘤缩小的患者中,联合组中位肿瘤缩小持续时间为3.8个月,单药组为2.1个月(HR 0.34,95%CI 0.22-0.53,P<0.0001)。
  • 联合组缓解深度幅度大于单药组。

核心结论

  • FTD/TPI联合贝伐珠单抗相较于FTD/TPI的生存获益可能与早期肿瘤缩小和缓解深度的改善相关。

研究设计与样本

  • SUNLIGHT试验的事后分析,评估难治性转移性结直肠癌患者接受FTD/TPI联合贝伐珠单抗或FTD/TPI治疗的肿瘤缩小、早期肿瘤缩小、肿瘤缩小持续时间和缓解深度。

主要发现

  • 联合组48%出现肿瘤缩小、39%出现早期肿瘤缩小,单药组分别为21%和17%。
  • 达到早期肿瘤缩小的患者中,联合组中位肿瘤缩小持续时间为3.8个月,单药组为2.1个月(HR 0.34,95%CI 0.22-0.53,P<0.0001)。
  • 联合组缓解深度幅度大于单药组。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This post hoc analysis of the SUNLIGHT trial sought to assess the response to treatment with trifluridine/tipiracil (FTD/TPI) + bevacizumab and FTD/TPI in patients with refractory metastatic colorectal cancer using tumor shrinkage (TS), early TS (ETS), duration of TS (DTS) and depth of response (DpR) as response-related parameters. METHODS: TS was defined as any decrease from baseline of the sum of the longest diameter of target lesions. TS at first assessment was specified as ETS. DpR was defined as the maximum percentage change from baseline of the sum of the longest diameters of target lesions. DTS was defined as the time from first TS to first increase in tumor size, progressive disease, or death. RESULTS: In the FTD/TPI + bevacizumab group, 48 % had TS and 39 % had ETS. In the FTD/TPI group, 21 % had TS and 17 % had ETS. In patients achieving ETS, median DTS was prolonged with FTD/TPI + bevacizumab compared to FTD/TPI (3.8 versus 2.1 months; HR: 0.34 [95 % CI: 0.22, 0.53]; P < 0.0001). Magnitude of DpR was greater with FTD/TPI + bevacizumab than with FTD/TPI. CONCLUSION: The survival benefit of treatment with FTD/TPI + bevacizumab versus FTD/TPI is likely associated with the improvement of ETS and DpR.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Taieb J, Modest DP, Fakih M, et al. Impact of trifluridine/tipiracil plus bevacizumab on tumor shrinkage and depth of response in refractory metastatic colorectal cancer: analysis of the SUNLIGHT trial. Eur J Cancer. 2025. PMID: 40694985. doi:10.1016/j.ejca.2025.115644

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。